NHL, B-cell type, primary Lymphoma of the central nervous system

• MATRIX - Rituximab 375 / Methotrexate 3500 / Cytarabine 2000 / Thiotepa 30, primary central nervous system Lymphoma, induction PID 703 V2.2 (2026-07-06)
  V2.2. Correction of title, adjustment of infection prophylaxis, addition of Furosemide as a standard option V2.1: Change to Methotrexate hydration according to Joerger 2018. V0.2: Optimization of the Thiotepa diluent volume to 100 ml to achieve a final concentration of 0.5?1.0 mg/ml for most patients. V1.1: Changed the administration days for Aciclovir; no administration concurrent with Methotrexate exposure V0.1: Substances in the fluid module merged for Cato Export. V0.1: Duration and sequence of cytostatic drugs according to the study protocol. Allergy prophylaxis for Rituximab according to the summary of product characteristics.
• MATRIX - Rituximab 375 / Carboplatin 300 / Ifosfamide 1.5 / Etoposide 100 / Dexamethasone 40, primary central nervous system Lymphoma, consolidation therapy PID 831 V2.1 (2026-07-06)
  V2.1: Correction to title V2.0: Correction to Dexamethasone vehicle volume to 50 ml on days 2?4. V1.1: Addition of "Matrix" to the short title V1.0: Cato test done. V0.1: Order and durations of administration of the substances, as well as infection prophylaxis and supportive therapy with Mesna, in accordance with the study protocol.

Protocols in Revision

Bladder Cancer

• Enfortumab Vedotin 1,25 / Pembrolizumab 200 - Pembrolizumab 200, Harnblasenkarzinom, perioperativ, Zyklus 10-17 PID 3148 V1.1
• Enfortumab Vedotin 1,25 / Pembrolizumab 200, Harnblasenkarzinom, perioperativ, Zyklus 1-9 PID 3147 V1.1

Hodgkin Lymphoma

• miniBEAM - Carmustine 60 / Etoposide 75 / Cytarabine 100 / Melphalan 30, Hodgkin Lymphoma PID 2381 V1.1

Gastric Cancer

• Atezolizumab 840 / FLOT (Docetaxel 50 / Oxaliplatin 85 / Folinsäure 200 / Fluorouracil 2600), Adenokarzinom ösophagogastraler Übergang und Magen, perioperativ, Zyklus 1-8 PID 2563 V1.1
• Nivolumab 240 / Ipilimumab 1, Adenokarzinom ösophagogastraler Übergang und Magen, neoadjuvant PID 2244 V1.1
• Nivolumab 480, Adenokarzinom ösophagogastraler Übergang und Magen, adjuvant PID 2245 V1.1

Multiple Myeloma

• HD 7 - Bortezomib 1.3 / Lenalidomide 25 / Dexamethasone 20, Multiple Myeloma, Induction, Cycle 1-3 PID 40 V1.1
• HD 7 - Lenalidomide 10 / Dexamethasone 20, Multiple Myeloma, maintenance, cycle 1 PID 43 V1.1
• HD 7 - Lenalidomide 10, multiple myeloma, maintenance, cycle 2-3 PID 44 V1.1
• HD 7 - Lenalidomide 15, multiple myeloma, maintenance, cycle 4+ PID 37 V1.1

NHL, B-cell type, primary Lymphoma of the central nervous system

• Cytarabine 2000 / Etoposide 5, primary lymphoma of the central nervous system, cycle 6 PID 1866 V1.1
• MATRIX - Carmustine 400 / Thiotepa 5, primary Lymphoma of the central nervous system, Stem Cell Transplantation, Autologous, MA PID 890 V2.2
• Rituximab 375 / Methotrexate 3000 / Procarbazine 60 - Procarbazine 100, maintenance, primary central nervous system Lymphoma PID 1031 V1.3
• Rituximab 375 / Methotrexate 3000 / Procarbazine 60, primary central nervous system Lymphoma, Cycle 1 PID 1191 V1.4
• Rituximab 375 / Methotrexate 3000 / Procarbazine 60, primary central nervous system Lymphoma, cycles 2?3 PID 1030 V2.4

Esophageal Cancer

• Atezolizumab 840 / FLOT (Docetaxel 50 / Oxaliplatin 85 / Folinsäure 200 / Fluorouracil 2600), Adenokarzinom ösophagogastraler Übergang und Magen, perioperativ, Zyklus 1-8 PID 2563 V1.1
• Nivolumab 240 / Ipilimumab 1, Adenokarzinom ösophagogastraler Übergang und Magen, neoadjuvant PID 2244 V1.1
• Nivolumab 480, Adenokarzinom ösophagogastraler Übergang und Magen, adjuvant PID 2245 V1.1